000109514 001__ 109514
000109514 005__ 20230519145559.0
000109514 0247_ $$2doi$$a10.3390/biomedicines9121775
000109514 0248_ $$2sideral$$a125912
000109514 037__ $$aART-2021-125912
000109514 041__ $$aeng
000109514 100__ $$0(orcid)0000-0002-6674-7364$$aAbás E.$$uUniversidad de Zaragoza
000109514 245__ $$aSelective anticancer and antimicrobial metallodrugs based on Gold(III) dithiocarbamate complexes
000109514 260__ $$c2021
000109514 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109514 5203_ $$aNew dithiocarbamate cycloaurated complexes have been synthesized and their physicochemical and in vitro antitumor properties have been evaluated. All the performed studies highlighted good transport through the blood and biodistribution, according to the balance between the properties of hydrophilicity/lipophilicity and the binding of moderate strength to the BSA protein. Furthermore, none of the complexes exhibited reduction or decomposition reactions, presenting excellent physiological stability. The in vitro cytotoxic effect was evaluated on human colon cancer cell line Caco-2/TC7, and the complexes showed great antiproliferative activity and excellent selectivity, as much less effect was detected on normal Caco-2/TC7 cells. Most of the complexes exhibit antiproliferative activity that was better than or similar to auranofin, and at least nine times better than that of cisplatin. Its action mechanism is still under discussion since no evidence of cell cycle arrest was found, but an antioxidant role was shown for some of the selective complexes. All complexes were also tested as antimicrobial drugs, exhibiting good activity towards S. aureus and E. coli. bacteria and C. albicans and C. neoformans fungi. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
000109514 536__ $$9info:eu-repo/grantAgreement/ES/DGA/A20-20R
000109514 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109514 590__ $$a4.757$$b2021
000109514 592__ $$a0.874$$b2021
000109514 594__ $$a3.0$$b2021
000109514 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b121 / 297 = 0.407$$c2021$$dQ2$$eT2
000109514 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000109514 591__ $$aPHARMACOLOGY & PHARMACY$$b87 / 279 = 0.312$$c2021$$dQ2$$eT1
000109514 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2021$$dQ1
000109514 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b62 / 140 = 0.443$$c2021$$dQ2$$eT2
000109514 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109514 700__ $$0(orcid)0000-0002-1829-6319$$aAguirre-Ramírez D.
000109514 700__ $$0(orcid)0000-0002-5801-3352$$aLaguna M.
000109514 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa L.$$uUniversidad de Zaragoza
000109514 7102_ $$12009$$2750$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cÁrea Química Analítica
000109514 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000109514 773__ $$g9, 12 (2021), [18 pp]$$tBiomedicines$$x2227-9059
000109514 8564_ $$s1860276$$uhttps://zaguan.unizar.es/record/109514/files/texto_completo.pdf$$yVersión publicada
000109514 8564_ $$s2826554$$uhttps://zaguan.unizar.es/record/109514/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109514 909CO $$ooai:zaguan.unizar.es:109514$$particulos$$pdriver
000109514 951__ $$a2023-05-18-15:58:29
000109514 980__ $$aARTICLE